The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic.
Michael R ZileAkshay S DesaiMaria Rosa CostanzoAnique DucharmeAlan MaiselMandeep R MehraSara PaulSamuel F SearsFrank SmartChristopher V ChienAshrith GuhaJason L GuichardShelley HallOrvar JonssonNessa JohnsonPoornima SoodJohn HendersonPhilip B AdamsonJoAnn LindenfeldPublished in: European heart journal (2022)
During COVID-19, the primary event rate decreased in the controls and remained low in the treatment group, resulting in an effacement of group differences that were present pre-COVID-19. These outcomes did not result from changes in provider- or disease-dependent factors; pulmonary artery pressure decreased despite fewer medication changes, suggesting that patient-dependent factors played an important role in these outcomes. Clinical Trials.gov: NCT03387813.
Keyphrases
- pulmonary artery
- coronary artery
- pulmonary hypertension
- pulmonary arterial hypertension
- clinical trial
- heart failure
- coronavirus disease
- sars cov
- phase ii
- phase iii
- healthcare
- primary care
- left ventricular
- acute heart failure
- type diabetes
- metabolic syndrome
- combination therapy
- randomized controlled trial
- cardiac resynchronization therapy
- weight loss
- respiratory syndrome coronavirus
- adverse drug
- electronic health record